Table 3.
Clinical data of previously reported study.
| Fang et al. (2017) | Ding et al. (2016) | Peng et al. (2017) | Song et al. (2017) | Ya (2016)* | Zhang et al., 2012a, Zhang et al., 2012b# | |
|---|---|---|---|---|---|---|
| Institute | The First Affiliated Hospital of Nanjing Medical University, Nanjing, China | Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China | China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China | Zhejiang Cancer Hospital, Hangzhou, China | Si Chuan Cancer Hospital, Chengdu, China | Twenty centers in China |
| Pathology | NSCLC, EGFR(–), ALK(–) | Poor differentiated adenocarcinoma, squamous carcinoma | NSCLC | NSCLC | Metastatic NSCLC, EGFR(–) | Non-squamous NSCLC |
| No. of patients | 3 | 2 | 1 | 42 | 20 | 90 |
| Line of treatment | Post third line | Second and forth line | Third line | Post second line | Post third line | Post third line |
| Dosage, mg/day | 500 | 850 | 250 or 500 | 500 | 500 | 750 |
| ORR | 100% | 50% | 100% | 9.5% | 30% | 20% |
| DCR | 100% | 100% | 100% | 61.9% | 85% | 68.9% |
| PR | 3/3 | 1/2 | 1/1 | 4/42 | NR | NR |
| SD | 0/3 | 1/2 | 0/1 | 22/42 | NR | 51/90 |
| PFS, months | 2.8–6.0 | 4.6, 6.0 | 5.1 | 4.2 | NR | 4.7 |
| OS, months | NR | NR | NR | 6.0 | 4 | NR |
| Adverse events (Grade 3/4) | 2/3 | NR | 1/1 | 21/42 | Hypertension (5%), HFS (5%), hemoptysis (5%) | NR |
Abbreviations: ALK, anaplastic lymphoma kinase; DCR, disease control rate; EGFR, epidermal growth factor receptor; HFS, hand-foot syndrome; NR, not reported; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease.
*
Presented at ESMO Asia 2016 Congress, only abstract available.
#
Presented at 2012 ASCO Annual Meeting, only abstract available.